(Q38111097)

29 August 2017

0 references

Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment (English)

1 reference

29 August 2017

1 reference

1 reference

Hans-Christoph Diener

1

object named as

Hans-Christoph Diener

1 reference

29 August 2017

Christian Foerch

2

1 reference

29 August 2017

Hanno Riess

3

1 reference

29 August 2017

Joachim Röther

4

1 reference

29 August 2017

Gerhard Schroth

5

1 reference

29 August 2017

Ralph Weber

6

1 reference

29 August 2017

language of work or name

1 reference

31 May 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

677-688

1 reference

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Antiplatelet therapy in cerebrovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Thrombolysis in stroke despite contraindications or warnings?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the A

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

The impact of recanalization on ischemic stroke outcome: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Prior use of antiplatelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Rapid reversal of anticoagulation prevents excessive secondary hemorrhage after thrombolysis in a thromboembolic model in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

How to design an opioid drug that causes reduced tolerance and dependence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Warfarin therapy does not increase risk of symptomatic intracerebral hemorrhage in eligible patients after intravenous thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Off-label thrombolysis is not associated with poor outcome in patients with stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Apixaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

A call for transparent reporting to optimize the predictive value of preclinical research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Point-of-care laboratory halves door-to-therapy-decision time in acute stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Reducing in-hospital delay to 20 minutes in stroke thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Intravenous thrombolysis in a stroke patient taking dabigatran.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Interpretation of point-of-care INR results in patients treated with dabigatran

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Laboratory assessment of new anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Measurement of the new anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Secondary preventive medication persistence and adherence 1 year after stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Determination of rivaroxaban in human plasma samples.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Assays for measuring rivaroxaban: their suitability and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Endovascular therapy after intravenous t-PA versus t-PA alone for stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Endovascular treatment for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

A trial of imaging selection and endovascular treatment for ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the MERCI and multi MERCI trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Three-month and long-term outcomes and their predictors in acute basilar artery occlusion treated with intra-arterial thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Endovascular therapy of 623 patients with anterior circulation stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

In vivo evaluation of the first dedicated combined flow-restoration and mechanical thrombectomy device in a swine model of acute vessel occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Use of the New Solitaire (TM) AB Device for Mechanical Thrombectomy when Merci Clot Retriever Has Failed to Remove the Clot. A Case Report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Impact of retrievable stents on acute ischemic stroke treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970101-7

7 January 2021

10.1016/S1474-4422(13)70101-7

Identifiers

DOI

1 reference

29 August 2017

1 reference